D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00 ...
Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...
BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...
D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...
4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...
BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
5d
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...
4D-310 is under development for the treatment of Fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that ...
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback